Whalesbook
Boosting Pharma Logistics
India's Department of Pharmaceuticals (DoP) is commissioning a major logistics study to significantly improve its pharmaceutical and medical device sectors. This effort goes beyond addressing the immediate impact of geopolitical events that have inflated shipping costs and transit times. It aims to fix long-standing structural issues. Historically, India's logistics and warehousing costs have been about 15% higher than global averages, with inventory holding periods averaging 98 days compared to the global best of 64 days. The study is crucial for making the sector more cost-competitive and resilient globally, aiming to solidify India's position as a leading exporter of high-value products, not just generics.
Disruptions Fueling the Overhaul
The urgency for this study is heightened by recent disruptions, including freight cost surges of over 200-300% and doubled transit times due to Red Sea diversions. These events have hit Indian pharma exports, forcing companies to hold larger inventories and potentially costing the sector hundreds of millions of dollars. The DoP recognizes that short-term crisis management isn't enough; a thorough overhaul of the logistics value chain, from sourcing to final delivery, is necessary. This involves assessing transport, storage, handling, and regulatory fees to find operational bottlenecks like cold-chain failures and customs delays. The government's National Logistics Policy (NLP) supports this goal, aiming to lower total logistics costs to under 5% of GDP.
Bridging the Efficiency Gap
Despite global leadership in generics and vaccines, India's pharmaceutical and medical device sectors face significant logistical hurdles that limit export growth. The 15% higher logistics costs and longer inventory times compared to international competitors directly reduce profit margins and price competitiveness. Cold chain infrastructure, vital for temperature-sensitive products like vaccines, is especially weak in rural areas, resulting in an estimated 25% of vaccines being compromised. The study will gather data from stakeholders to map supply chains and find ways to improve cold chain integrity, transport options, and customs processes. This effort also supports India's aim to shift from a generics-focused model to a hub for innovation in biologics and biosimilars, which require advanced logistics. The MedTech sector shares these challenges, with a large trade deficit showing reliance on imports for advanced devices.
Addressing Deep-Rooted Challenges
While the DoP's initiative is important, its success depends on tackling deep-rooted problems. The sustained 15% higher logistics costs and longer inventory cycles are fundamental issues stemming from underdeveloped infrastructure and fragmented supply chains, not just operational problems. Some parts of the industry still rely on manual processes, leading to increased costs and delays. Solving these issues will require strong policy changes and substantial investment in infrastructure like ports, logistics hubs, and digital systems, aligning with the National Logistics Policy. The study must also consider global regulatory demands, which create obstacles for export growth. For example, MedTech companies struggle to meet international standards, contributing to the sector's trade deficit. The consultancy's findings will be key to driving real improvements, especially in cold chain management, where capacity is limited and rural access is poor.
Path Forward for Supply Chains
The DoP's study is set to be a major step in transforming India's pharma and MedTech supply chains. By finding and recommending solutions for logistics issues, the initiative aims to achieve greater cost savings, improve product quality and safety through better cold chains, and boost India's global export competitiveness. Success means not only easing the effects of current geopolitical crises but also building a strong, modern, and efficient logistics system that supports growth in areas like biologics, biosimilars, and advanced medical devices. The anticipated results include making Indian pharma and medical products more competitive abroad, reducing dependence on expensive imports, and securing a stronger global healthcare market position.